Consensus $8.01. Raises FY26 revenue view to $3.3B-$3.35B from $3.22B-$3.28B, consensus $3.25B. Capital spending guidance is unchanged from a range of $250M-$275M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical reports Q1 adjusted EPS $2.13, consensus $1.68
- WST Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- West Pharmaceutical price target raised to $275 from $265 at Barclays
- West Pharmaceutical expands Damastown, Dublin facility
- Orderly Leadership Transition and Reaffirmed 2026 Targets Underpin Buy Rating on West Pharmaceutical